TWI559931B - Combination therapy with an anti-ang2 antibody and a cd40 agonist - Google Patents

Combination therapy with an anti-ang2 antibody and a cd40 agonist

Info

Publication number
TWI559931B
TWI559931B TW103144626A TW103144626A TWI559931B TW I559931 B TWI559931 B TW I559931B TW 103144626 A TW103144626 A TW 103144626A TW 103144626 A TW103144626 A TW 103144626A TW I559931 B TWI559931 B TW I559931B
Authority
TW
Taiwan
Prior art keywords
agonist
combination therapy
ang2 antibody
ang2
antibody
Prior art date
Application number
TW103144626A
Other languages
English (en)
Other versions
TW201526915A (zh
Inventor
Christian Klein
Philipp Mueller
Markus Thomas
Alfred Zippelius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW201526915A publication Critical patent/TW201526915A/zh
Application granted granted Critical
Publication of TWI559931B publication Critical patent/TWI559931B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103144626A 2013-12-20 2014-12-19 Combination therapy with an anti-ang2 antibody and a cd40 agonist TWI559931B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198753 2013-12-20
EP14158331 2014-03-07

Publications (2)

Publication Number Publication Date
TW201526915A TW201526915A (zh) 2015-07-16
TWI559931B true TWI559931B (en) 2016-12-01

Family

ID=52278610

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103144626A TWI559931B (en) 2013-12-20 2014-12-19 Combination therapy with an anti-ang2 antibody and a cd40 agonist

Country Status (20)

Country Link
US (3) US20150232548A1 (zh)
EP (1) EP3082857B1 (zh)
JP (1) JP6345787B2 (zh)
KR (1) KR20160085888A (zh)
CN (1) CN105611944A (zh)
AU (1) AU2014368695A1 (zh)
BR (1) BR112016007112A2 (zh)
CA (1) CA2923591A1 (zh)
CL (1) CL2016001586A1 (zh)
CR (1) CR20160199A (zh)
EA (1) EA201600474A1 (zh)
HK (1) HK1221409A1 (zh)
IL (1) IL244454A0 (zh)
MX (1) MX2016008099A (zh)
PE (1) PE20160753A1 (zh)
PH (1) PH12016500482A1 (zh)
SG (1) SG11201604594SA (zh)
TW (1) TWI559931B (zh)
WO (1) WO2015091655A1 (zh)
ZA (1) ZA201601895B (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
DK3180087T3 (da) 2014-08-12 2019-05-13 Alligator Bioscience Ab Kombinationsterapier med anti cd40-antistoffer
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
MX2017005642A (es) * 2014-11-10 2017-07-24 Hoffmann La Roche Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
CA2963719A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-il-1beta antibodies and methods of use
EP3313880A1 (en) 2015-06-29 2018-05-02 Bristol-Myers Squibb Company Antibodies to cd40
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017218953A1 (en) * 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
SG11202004864TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
JP7177284B2 (ja) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド 抗ａｎｇ２抗体及びその用途
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN112168960A (zh) * 2019-07-03 2021-01-05 义慧科技(深圳)有限公司 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026328A (en) * 2008-12-16 2010-07-16 Hoffmann La Roche Antibodies against human angiopoietin 2
TW201138820A (en) * 2010-03-26 2011-11-16 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026328A (en) * 2008-12-16 2010-07-16 Hoffmann La Roche Antibodies against human angiopoietin 2
TW201138820A (en) * 2010-03-26 2011-11-16 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies

Also Published As

Publication number Publication date
MX2016008099A (es) 2016-10-13
KR20160085888A (ko) 2016-07-18
TW201526915A (zh) 2015-07-16
US20150232548A1 (en) 2015-08-20
US20180134780A1 (en) 2018-05-17
AU2014368695A1 (en) 2016-04-14
BR112016007112A2 (pt) 2017-09-19
EA201600474A1 (ru) 2016-11-30
EP3082857B1 (en) 2018-07-25
EP3082857A1 (en) 2016-10-26
HK1221409A1 (zh) 2017-06-02
PH12016500482A1 (en) 2016-05-16
IL244454A0 (en) 2016-04-21
CL2016001586A1 (es) 2017-05-12
CA2923591A1 (en) 2015-06-25
US20200199215A1 (en) 2020-06-25
CR20160199A (es) 2016-06-17
JP2017504600A (ja) 2017-02-09
WO2015091655A1 (en) 2015-06-25
SG11201604594SA (en) 2016-07-28
PE20160753A1 (es) 2016-08-01
JP6345787B2 (ja) 2018-06-20
ZA201601895B (en) 2018-11-28
CN105611944A (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
ZA201601895B (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
IL283040A (en) Electronic smoking part and electronic smoking device
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
SG10201708409VA (en) Medicament device
EP2992870A4 (en) COINJECTION DEVICE AND COINJECTION PROCESS
EP3145565A4 (en) Combined laryngo-tracheal anesthetic and stylet device
HK1214972A1 (zh) 與注射裝置起使用的輔助裝置
EP2983670A4 (en) Ibrutinib combination therapy
EP3081627A4 (en) Well plate and subject selection device provided with well plate
EP2965772A4 (en) MEDICATION INJECTION DEVICE AND STORAGE CONTAINER THEREFOR
EP2974377A4 (en) ELECTROMAGNETIC TRANSDUCER HAVING SPECIFIC INTERNAL GEOMETRY
PL3054856T3 (pl) Urządzenie do zsynchronizowanego wstrzykiwania i zasysania
GB201317955D0 (en) Metering device and parts therefor
HK1224233A1 (zh) 注射器以及注射器組件
IL242785B (en) A signature matching device and an object provided with a signature matching device
EP3010577A4 (en) Radioactive therapeutic device with fixation
EP3067080A4 (en) MEDICATION INJECTION DEVICE
SI2971810T1 (sl) Pohištveno okovje s pritrdilno napravo
EP2979200A4 (en) CHARACTERISTICS AND QUESTIONS
EP3088024A4 (en) Drug injection device
HK1223266A1 (zh) 藥劑供給單元及藥劑供給裝置
EP3027264A4 (en) Nanochanneled device with electrodes and related methods
EP2997998A4 (en) Therapy device for edema and neuropathy
GB201311107D0 (en) Bioorthogonal methods and compounds
EP3067078A4 (en) MEDICATION INJECTION DEVICE

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees